Olodaterol + Tiotropium bromide (Olodaterol + Tiotropium bromide)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Beta-adrenomimetics

M-holinoblokatory

Included in the formulation
  • Spiolto® Respimat®
    solution d / inhal. 
    Boehringer Ingelheim International GmbH     Germany
    • АТХ:

    R.03.A.L.06   Olodaterol and tiotropium bromide

    Pharmacodynamics:

    Combined bronchodilator.

    Olodaterol

    Selectively activates β2-adrenoceptors of the respiratory tract, thereby stimulating intracellular adenylate cyclase, which is involved in the synthesis of cyclic adenosine monophosphate (cAMP). An increase in the amount of cAMP results in relaxation of the smooth muscle muscles of the bronchi.

    Tiotropium bromide

    M-holinoblokator local action. Selectively blocks m-holinoretseptory muscles of the bronchi. Has a pronounced and prolonged bronchodilator effect. Promotes thickening of phlegm.

    Pharmacokinetics:

    Olodaterol

    After inhalation, the maximum concentration in the blood plasma is reached after 5-7 minutes. Bioavailability is 33%. The connection with plasma proteins is 60%.

    Does not penetrate the blood-brain barrier.

    The half-life is 27-45 hours.

    Tiotropium bromide

    After inhalation, the maximum concentration in the blood plasma is reached after 5-7 minutes. Bioavailability is 2-3%. The connection with plasma proteins is 72%.

    Does not penetrate the blood-brain barrier.

    The half-life is 27 hours. Elimination by the kidneys.

    Indications:

    It is used for maintenance therapy of patients with chronic obstructive pulmonary disease, emphysema and chronic bronchitis.

    ICD-10

    X.J40-J47.J42   Chronic bronchitis, unspecified

    X.J40-J47.J43   Emphysema

    X.J40-J47.J44   Other chronic obstructive pulmonary disease

    X.J40-J47.J44.9   Chronic obstructive pulmonary disease, unspecified

    Contraindications:

    Closed-angle glaucoma, age under 18 years, individual intolerance.

    Carefully:

    Diabetes mellitus, thyrotoxicosis, cardiovascular diseases, myocardial infarction in the anamnesis, convulsions, bladder neck obstruction, productive cough, age over 40 years - the risk of undiagnosed glaucoma, pregnancy and lactation, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - category is not defined. It is used with caution, in cases where the expected effect exceeds the risk to the fetus and newborn.

    Dosing and Administration:

    Inhalation, once a day, 2 inhalation doses.

    The highest daily dose: 2 inhalation doses.

    The highest single dose: 2 inhalation doses.

    Side effects:

    Olodaterol

    Central and peripheral nervous system: dizziness, headache, insomnia, anxiety, tremor.

    Respiratory system: cough, pharyngitis, bronchospasm. Nose bleed.

    The cardiovascular system: myocardial ischemia, tachycardia, arrhythmia, arterial hypertension.

    Digestive system: dry mouth, gastroesophageal reflux, glossitis, gingivitis, stomatitis.

    Musculoskeletal system: cramps, arthralgia, back pain.

    Dermatological reactions: dry skin.

    Sense organs: dysphonia.

    urinary system: retention of urine.

    Allergic reactions.

    Tiotropium bromide

    Digestive system: Perspiration in the throat, dry mouth.

    Sense organs: increased intraocular pressure, spasm of accommodation, impaired vision.

    Allergic reactions.

    Overdose:

    Olodaterol

    Metabolic acidosis, hypokalemia, hyperglycemia, bronchospasm, cardiac arrest, increased urinary retention.

    Tiotropium bromide

    Dry mouth, conjunctivitis.

    Treatment is symptomatic.

    Interaction:

    Clinically significant interactions are not described.

    Special instructions:

    The drug is not used to treat bronchial asthma.

    When taking the drug is not recommended driving and working with moving machinery.

    Instructions
    Up